Novome Biotechnologies

📍 South San Francisco, United States🗓 Founded 2016👥 13 employees💰 Last funded Jan 2020
Biotechnology Research🌐 novomebio.com
Website LinkedIn
Novome is building genetically engineered microbial medicines (GEMMs) that perform defined activities in the human gut to treat chronic diseases. We have developed the first platform for controlled colonization of the gut with engineered therapeutic bacteria, and are applying this to multiple disease areas as well as expanding our platform capabilities. Our lead program in enteric hyperoxaluria is currently in Phase 2 clinical trials, and we are focusing current research efforts on making a microbial cell therapy to treat inflammatory bowel disease (IBD).
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Novome Biotechnologies?
Novome Biotechnologies has 2 investors on record on gritt.io, 2 mid-stage.
When did Novome Biotechnologies last raise funding?
The most recent investment in Novome Biotechnologies recorded on gritt.io was in January 2020.
When was Novome Biotechnologies founded?
Novome Biotechnologies was founded in 2016.
What industry is Novome Biotechnologies in?
Novome Biotechnologies operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Novome Biotechnologies based?
Novome Biotechnologies is headquartered in South San Francisco, United States.